Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 92 entries
Sorted by: Best Match Show Resources per page
The Ecology and Evolution of Microbial Defense Systems in Escherichia coli.

EcoSal Plus

Riley MA, Wertz JE, Goldstone C.
PMID: 26443346
EcoSal Plus. 2004 Dec;1(1). doi: 10.1128/ecosalplus.6.4.8.

Microbes produce an extraordinary array of microbial defense systems. These include broad-spectrum classical antibiotics critical to human health concerns; metabolic by-products, such as the lactic acids produced by lactobacilli; lytic agents, such as lysozymes found in many foods; and...

Cite
Riley MA, Wertz JE, Goldstone C. The Ecology and Evolution of Microbial Defense Systems in Escherichia coli. EcoSal Plus. 2004;1(1)doi: 10.1128/ecosalplus.6.4.8.
Riley, M. A., Wertz, J. E., & Goldstone, C. (2004). The Ecology and Evolution of Microbial Defense Systems in Escherichia coli. EcoSal Plus, 1(1), . https://doi.org/10.1128/ecosalplus.6.4.8
Riley, Margaret A, et al. "The Ecology and Evolution of Microbial Defense Systems in Escherichia coli." EcoSal Plus vol. 1,1 (2004). doi: https://doi.org/10.1128/ecosalplus.6.4.8
Riley MA, Wertz JE, Goldstone C. The Ecology and Evolution of Microbial Defense Systems in Escherichia coli. EcoSal Plus. 2004 Dec;1(1). doi: 10.1128/ecosalplus.6.4.8. PMID: 26443346.
Copy Download .nbib Format: NLM
Cytokine response to staphylococcal exotoxins in Staphylococcus aureus septicemia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Söderquist B, Kanclerski K, Sundqvist KG, Colque-Navarro P, Holmberg H, Vikerfors T, Möllby R.
PMID: 11864351
Clin Microbiol Infect. 1998 Jul;4(7):366-372. doi: 10.1111/j.1469-0691.1998.tb00080.x.

OBJECTIVE: To investigate if exposure to exotoxins results in augmented serum cytokine response of patients with Staphylococcus aureus septicemia. METHODS: Serum samples and strains from 63 patients with S. aureus septicemia were collected in a prospective study. Toxin production...

Cite
Söderquist B, Kanclerski K, Sundqvist KG, et al. Cytokine response to staphylococcal exotoxins in Staphylococcus aureus septicemia. Clin Microbiol Infect. 1998;4(7):366-372doi: 10.1111/j.1469-0691.1998.tb00080.x.
Söderquist, B., Kanclerski, K., Sundqvist, K. G., Colque-Navarro, P., Holmberg, H., Vikerfors, T., & Möllby, R. (1998). Cytokine response to staphylococcal exotoxins in Staphylococcus aureus septicemia. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 4(7), 366-372. https://doi.org/10.1111/j.1469-0691.1998.tb00080.x
Söderquist, Bo, et al. "Cytokine response to staphylococcal exotoxins in Staphylococcus aureus septicemia." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 4,7 (1998): 366-372. doi: https://doi.org/10.1111/j.1469-0691.1998.tb00080.x
Söderquist B, Kanclerski K, Sundqvist KG, Colque-Navarro P, Holmberg H, Vikerfors T, Möllby R. Cytokine response to staphylococcal exotoxins in Staphylococcus aureus septicemia. Clin Microbiol Infect. 1998 Jul;4(7):366-372. doi: 10.1111/j.1469-0691.1998.tb00080.x. PMID: 11864351.
Copy Download .nbib Format: NLM
Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Current infectious disease reports

Baracco GJ, Bisno AL.
PMID: 11095793
Curr Infect Dis Rep. 1999 Aug;1(3):230-237. doi: 10.1007/s11908-999-0024-4.

The streptococcal toxic shock syndrome (STSS) is a severe, life-threatening condition characterized by hypotension and multiorgan system dysfunction associated with infection by the group A Streptococcus (GAS) or rarely by streptococci of other Lancefield serogroups. It is associated with...

Cite
Baracco GJ, Bisno AL. Therapeutic Approaches to Streptococcal Toxic Shock Syndrome. Curr Infect Dis Rep. 1999;1(3):230-237doi: 10.1007/s11908-999-0024-4.
Baracco, G. J., & Bisno, A. L. (1999). Therapeutic Approaches to Streptococcal Toxic Shock Syndrome. Current infectious disease reports, 1(3), 230-237. https://doi.org/10.1007/s11908-999-0024-4
Baracco, and Bisno. "Therapeutic Approaches to Streptococcal Toxic Shock Syndrome." Current infectious disease reports vol. 1,3 (1999): 230-237. doi: https://doi.org/10.1007/s11908-999-0024-4
Baracco GJ, Bisno AL. Therapeutic Approaches to Streptococcal Toxic Shock Syndrome. Curr Infect Dis Rep. 1999 Aug;1(3):230-237. doi: 10.1007/s11908-999-0024-4. PMID: 11095793.
Copy Download .nbib Format: NLM
Clostridium sordellii toxic shock syndrome: a case report and review of the literature.

Infectious diseases in obstetrics and gynecology

Sosolik RC, Savage BA, Vaccarello L.
PMID: 18476062
Infect Dis Obstet Gynecol. 1996;4(1):31-5. doi: 10.1155/S1064744996000087.

BACKGROUND: Since the 1980s, there have been isolated reports of a toxic shock syndrome associated with Clostridium sordellii necrotizing subcutaneous infections during the puerperium. Relatively localized fascial and muscle necrosis is noted at the surgical incision sites. However, circulating...

Cite
Sosolik RC, Savage BA, Vaccarello L. Clostridium sordellii toxic shock syndrome: a case report and review of the literature. Infect Dis Obstet Gynecol. 1996;4(1):31-5doi: 10.1155/S1064744996000087.
Sosolik, R. C., Savage, B. A., & Vaccarello, L. (1996). Clostridium sordellii toxic shock syndrome: a case report and review of the literature. Infectious diseases in obstetrics and gynecology, 4(1), 31-5. https://doi.org/10.1155/S1064744996000087
Sosolik, R C, et al. "Clostridium sordellii toxic shock syndrome: a case report and review of the literature." Infectious diseases in obstetrics and gynecology vol. 4,1 (1996): 31-5. doi: https://doi.org/10.1155/S1064744996000087
Sosolik RC, Savage BA, Vaccarello L. Clostridium sordellii toxic shock syndrome: a case report and review of the literature. Infect Dis Obstet Gynecol. 1996;4(1):31-5. doi: 10.1155/S1064744996000087. PMID: 18476062; PMCID: PMC2364462.
Copy Download .nbib Format: NLM
Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.

Journal of immune based therapies and vaccines

Kelly CD, O'Loughlin C, Gelder FB, Peterson JW, Sower LE, Cirino NM.
PMID: 17953756
J Immune Based Ther Vaccines. 2007 Oct 22;5:11. doi: 10.1186/1476-8518-5-11.

BACKGROUND: There is a clear need for vaccines and therapeutics for potential biological weapons of mass destruction and emerging diseases. Anthrax, caused by the bacterium Bacillus anthracis, has been used as both a biological warfare agent and bioterrorist weapon...

Cite
Kelly CD, O'Loughlin C, Gelder FB, et al. Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines. 2007;5:11doi: 10.1186/1476-8518-5-11.
Kelly, C. D., O'Loughlin, C., Gelder, F. B., Peterson, J. W., Sower, L. E., & Cirino, N. M. (2007). Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. Journal of immune based therapies and vaccines, 511. https://doi.org/10.1186/1476-8518-5-11
Kelly, Cassandra D, et al. "Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant." Journal of immune based therapies and vaccines vol. 5 (2007): 11. doi: https://doi.org/10.1186/1476-8518-5-11
Kelly CD, O'Loughlin C, Gelder FB, Peterson JW, Sower LE, Cirino NM. Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines. 2007 Oct 22;5:11. doi: 10.1186/1476-8518-5-11. PMID: 17953756; PMCID: PMC2104530.
Copy Download .nbib Format: NLM
Staphylococcal vaccines and immunotherapies.

Infectious disease clinics of North America

Schaffer AC, Lee JC.
PMID: 19135920
Infect Dis Clin North Am. 2009 Mar;23(1):153-71. doi: 10.1016/j.idc.2008.10.005.

Staphylococcus aureus is an important pathogen in the hospital and in the community, and it is increasingly resistant to multiple antibiotics. A nonantimicrobial approach to controlling S aureus is needed. The most extensively tested vaccine against S aureus, which...

Cite
Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am. 2009;23(1):153-71doi: 10.1016/j.idc.2008.10.005.
Schaffer, A. C., & Lee, J. C. (2009). Staphylococcal vaccines and immunotherapies. Infectious disease clinics of North America, 23(1), 153-71. https://doi.org/10.1016/j.idc.2008.10.005
Schaffer, Adam C, and Lee, Jean C. "Staphylococcal vaccines and immunotherapies." Infectious disease clinics of North America vol. 23,1 (2009): 153-71. doi: https://doi.org/10.1016/j.idc.2008.10.005
Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am. 2009 Mar;23(1):153-71. doi: 10.1016/j.idc.2008.10.005. PMID: 19135920.
Copy Download .nbib Format: NLM
The antibody molecule.

Methods in molecular medicine

George AJ.
PMID: 21337079
Methods Mol Med. 2000;40:1-21. doi: 10.1385/1-59259-076-4:1.

The importance of antibody molecules was first recognized in the 1890s, when it was shown that immunity to tetanus and diphtheria was caused by antibodies against the bacterial exotoxins (1). Around the same time, it was shown that antisera...

Cite
George AJ. The antibody molecule. Methods Mol Med. 2000;40:1-21doi: 10.1385/1-59259-076-4:1.
George, A. J. (2000). The antibody molecule. Methods in molecular medicine, 401-21. https://doi.org/10.1385/1-59259-076-4:1
George, A J. "The antibody molecule." Methods in molecular medicine vol. 40 (2000): 1-21. doi: https://doi.org/10.1385/1-59259-076-4:1
George AJ. The antibody molecule. Methods Mol Med. 2000;40:1-21. doi: 10.1385/1-59259-076-4:1. PMID: 21337079.
Copy Download .nbib Format: NLM
Lectin inhibition of bacterial adhesion to animal cells.

Methods in molecular medicine

Stinson MW, Wang JR.
PMID: 21374490
Methods Mol Med. 1998;9:529-37. doi: 10.1385/0-89603-396-1:529.

Adhesion of bacteria to epithelial cells of the respiratory, gastric, and genitourinary mucosa is generally considered to be the initial step in the pathogenesis of many bacterial infections (1). Adhesion enables the bacteria to localize near a food source...

Cite
Stinson MW, Wang JR. Lectin inhibition of bacterial adhesion to animal cells. Methods Mol Med. 1998;9:529-37doi: 10.1385/0-89603-396-1:529.
Stinson, M. W., & Wang, J. R. (1998). Lectin inhibition of bacterial adhesion to animal cells. Methods in molecular medicine, 9529-37. https://doi.org/10.1385/0-89603-396-1:529
Stinson, M W, and Wang, J R. "Lectin inhibition of bacterial adhesion to animal cells." Methods in molecular medicine vol. 9 (1998): 529-37. doi: https://doi.org/10.1385/0-89603-396-1:529
Stinson MW, Wang JR. Lectin inhibition of bacterial adhesion to animal cells. Methods Mol Med. 1998;9:529-37. doi: 10.1385/0-89603-396-1:529. PMID: 21374490.
Copy Download .nbib Format: NLM
Why bacteriophage encode exotoxins and other virulence factors.

Evolutionary bioinformatics online

Abedon ST, Lejeune JT.
PMID: 19325857
Evol Bioinform Online. 2007 Feb 28;1:97-110.

This study considers gene location within bacteria as a function of genetic element mobility. Our emphasis is on prophage encoding of bacterial virulence factors (VFs). At least four mechanisms potentially contribute to phage encoding of bacterial VFs: (i) Enhanced...

Cite
Abedon ST, Lejeune JT. Why bacteriophage encode exotoxins and other virulence factors. Evol Bioinform Online. 2007;1:97-110
Abedon, S. T., & Lejeune, J. T. (2007). Why bacteriophage encode exotoxins and other virulence factors. Evolutionary bioinformatics online, 197-110.
Abedon, Stephen T, and Lejeune, Jeffrey T. "Why bacteriophage encode exotoxins and other virulence factors." Evolutionary bioinformatics online vol. 1 (2007): 97-110.
Abedon ST, Lejeune JT. Why bacteriophage encode exotoxins and other virulence factors. Evol Bioinform Online. 2007 Feb 28;1:97-110. PMID: 19325857; PMCID: PMC2658872.
Copy Download .nbib Format: NLM
Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland : first surveillance report.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Aramburu C, Harbarth S, Liassine N, Girard M, Gervaix A, Scherenzel J, Renzi G, Sudre P.
PMID: 29208105
Euro Surveill. 2006 Jan;11(1):11-12. doi: 10.2807/esm.11.01.00594-en.

Methicillin resistant Staphylococcus Aureus (MRSA) infection is an emerging community pathogen. Community-acquired MRSA (CA-MRSA) has been associated with virulent strains producing Panton-Valentine leukocidin (PVL) and a variety of other exotoxins. In Geneva, PVL-producing CA-MRSA was first reported in 2002...

Cite
Aramburu C, Harbarth S, Liassine N, et al. Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland : first surveillance report. Euro Surveill. 2006;11(1):11-12doi: 10.2807/esm.11.01.00594-en.
Aramburu, C., Harbarth, S., Liassine, N., Girard, M., Gervaix, A., Scherenzel, J., Renzi, G., & Sudre, P. (2006). Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland : first surveillance report. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 11(1), 11-12. https://doi.org/10.2807/esm.11.01.00594-en
Aramburu, C, et al. "Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland : first surveillance report." Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin vol. 11,1 (2006): 11-12. doi: https://doi.org/10.2807/esm.11.01.00594-en
Aramburu C, Harbarth S, Liassine N, Girard M, Gervaix A, Scherenzel J, Renzi G, Sudre P. Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland : first surveillance report. Euro Surveill. 2006 Jan;11(1):11-12. doi: 10.2807/esm.11.01.00594-en. PMID: 29208105.
Copy Download .nbib Format: NLM
Low concentrations of local honey modulate Exotoxin A expression, and quorum sensing related virulence in drug-resistant .

Iranian journal of basic medical sciences

Ahmed AA, Salih FA.
PMID: 31217939
Iran J Basic Med Sci. 2019 May;22(5):568-575. doi: 10.22038/ijbms.2019.33077.7902.

OBJECTIVES: Honey's ability to kill microorganisms and even eradication of chronic infections with drug-resistant pathogens has been documented by numerous studies. The present study is focused on the action of honey in its sub-inhibitory levels to impact on the...

Cite
Ahmed AA, Salih FA. Low concentrations of local honey modulate Exotoxin A expression, and quorum sensing related virulence in drug-resistant . Iran J Basic Med Sci. 2019;22(5):568-575doi: 10.22038/ijbms.2019.33077.7902.
Ahmed, A. A., & Salih, F. A. (2019). Low concentrations of local honey modulate Exotoxin A expression, and quorum sensing related virulence in drug-resistant . Iranian journal of basic medical sciences, 22(5), 568-575. https://doi.org/10.22038/ijbms.2019.33077.7902
Ahmed, Akhter A, and Salih, Fraidoon A. "Low concentrations of local honey modulate Exotoxin A expression, and quorum sensing related virulence in drug-resistant ." Iranian journal of basic medical sciences vol. 22,5 (2019): 568-575. doi: https://doi.org/10.22038/ijbms.2019.33077.7902
Ahmed AA, Salih FA. Low concentrations of local honey modulate Exotoxin A expression, and quorum sensing related virulence in drug-resistant . Iran J Basic Med Sci. 2019 May;22(5):568-575. doi: 10.22038/ijbms.2019.33077.7902. PMID: 31217939; PMCID: PMC6556501.
Copy Download .nbib Format: NLM
Risk of Bacteriophage Therapeutics to Transfer Genetic Material and Contain Contaminants Beyond Endotoxins with Clinically Relevant Mitigation Strategies.

Infection and drug resistance

Doub JB.
PMID: 34992389
Infect Drug Resist. 2021 Dec 23;14:5629-5637. doi: 10.2147/IDR.S341265. eCollection 2021.

Bacteriophage therapy is a promising adjuvant therapeutic in the treatment of multidrug-resistant infections and chronic biofilm infections. However, there is limited knowledge about how to best utilize these agents in vivo, leading to a wide range of treatment protocols....

Cite
Doub JB. Risk of Bacteriophage Therapeutics to Transfer Genetic Material and Contain Contaminants Beyond Endotoxins with Clinically Relevant Mitigation Strategies. Infect Drug Resist. 2021;14:5629-5637doi: 10.2147/IDR.S341265.
Doub, J. B. (2021). Risk of Bacteriophage Therapeutics to Transfer Genetic Material and Contain Contaminants Beyond Endotoxins with Clinically Relevant Mitigation Strategies. Infection and drug resistance, 145629-5637. https://doi.org/10.2147/IDR.S341265
Doub, James B. "Risk of Bacteriophage Therapeutics to Transfer Genetic Material and Contain Contaminants Beyond Endotoxins with Clinically Relevant Mitigation Strategies." Infection and drug resistance vol. 14 (2021): 5629-5637. doi: https://doi.org/10.2147/IDR.S341265
Doub JB. Risk of Bacteriophage Therapeutics to Transfer Genetic Material and Contain Contaminants Beyond Endotoxins with Clinically Relevant Mitigation Strategies. Infect Drug Resist. 2021 Dec 23;14:5629-5637. doi: 10.2147/IDR.S341265. eCollection 2021. PMID: 34992389; PMCID: PMC8711558.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 92 entries